)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
Monte Rosa Therapeutic
Monte Rosa Therapeutic (GLUE) investor relations material
Monte Rosa Therapeutic Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary17 Mar, 2026
Executive summary
Positive interim Phase 1 data for NEK7-directed MGD MRT-8102 showed significant CRP reductions in subjects at elevated cardiovascular risk, with further readouts expected in H2 2026.
MRT-8102 demonstrated a favorable safety profile in SAD/MAD cohorts, with no serious adverse events and a broad therapeutic window.
Multiple Phase 2 studies for MRT-8102 are planned in CVD risk, gout flares, and hidradenitis suppurativa, starting H2 2026 through H1 2027.
MRT-2359 in combination with enzalutamide showed a 100% PSA response rate in mCRPC patients with AR mutations; Phase 2 study with apalutamide to begin Q3 2026.
VAV1-directed MGD MRT-6160 is advancing toward multiple Phase 2 studies in immune-mediated diseases in collaboration with Novartis.
Financial highlights
Collaboration revenue for Q4 2025 was $2.8M (down from $60.6M in Q4 2024); full-year 2025 revenue was $123.7M (up from $75.6M in 2024).
R&D expenses for Q4 2025 were $42.0M (up from $38.9M in Q4 2024); full-year R&D expenses were $141.5M (up from $121.6M in 2024).
Net loss for Q4 2025 was $46.1M (vs. $13.4M in Q4 2024); full-year net loss was $38.6M (improved from $72.7M in 2024).
Cash, cash equivalents, and marketable securities totaled $382.1M as of Dec 31, 2025.
$345M upsized follow-on financing in January 2026 further strengthened the balance sheet.
Outlook and guidance
Cash runway expected to fund operations and capital expenditures into 2029.
Anticipated readout of GFORCE-1 study for MRT-8102 in H2 2026; multiple Phase 2 studies to initiate from H2 2026 through H1 2027.
Phase 2 study of MRT-2359 with apalutamide in mCRPC to start in Q3 2026.
IND submission for cyclin E1-directed MGD and second-generation NEK7-directed MGD planned for 2026.
NEK7 degradation impact on body composition
Rationale for MRT-2359 and apalutamide Phase 2
MRT-6160 profit-sharing and co-funding terms
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Monte Rosa Therapeutic
- Advancing highly selective oral degraders for major unmet needs in immunology and oncology.GLUE
Corporate presentation17 Mar 2026 - Major data updates and new phase II trials in I&I and oncology expected in 2024.GLUEBarclays 28th Annual Global Healthcare Conference10 Mar 2026
- Multiple phase II trials and new INDs planned in 2024, with strong data in NEK7 and GSPT1 programs.GLUETD Cowen 46th Annual Health Care Conference2 Mar 2026
- MRT-8102 achieved 85% CRP reduction, strong cytokine suppression, and favorable safety in Phase 1.GLUEStudy Result3 Feb 2026
- AI-driven molecular glue degraders advance in oncology and immunology with multiple INDs ahead.GLUEUBS Targeted Protein Degradation Day 20243 Feb 2026
- Multiple clinical catalysts ahead as molecular glue degrader programs advance in oncology and immunology.GLUE2024 Wells Fargo Healthcare Conference22 Jan 2026
- Broad pipeline advances with molecular glue degraders and a landmark Novartis immunology deal.GLUEJefferies London Healthcare Conference 202413 Jan 2026
- Proprietary AI-driven platform fuels diverse pipeline and partnerships, with strong cash runway.GLUEPiper Sandler 36th Annual Healthcare Conference12 Jan 2026
- Multiple first-in-class protein degrader programs advance toward major clinical milestones in 2024.GLUE43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026
Next Monte Rosa Therapeutic earnings date
Q1 20268 May, 2026
Monte Rosa Therapeutic
Next Monte Rosa Therapeutic earnings date
Q1 20268 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage